Landscape of genetic lesions in 944 patients with myelodysplastic syndromes

Cited by (999)

Items 101–200 of 999

1. Dysregulation of the TET family of epigenetic regulators in lymphoid and myeloid malignancies
   Chan‐Wang Jerry Lio, Hiroshi Yuita, Anjana Rao · 2019 · Blood
2. Revisiting guidelines for integration of flow cytometry results in the WHO classification of myelodysplastic syndromes—proposal from the International/European LeukemiaNet Working Group for Flow Cytometry in MDS
   Anna Porwit‐MacDonald, Arjan A. van de Loosdrecht, Peter Bettelheim, Lisa Eidenschink Brodersen, Kate Burbury, Eline M.P. Cremers, Matteo Giovanni Della Porta, Robin M. Ireland, Ulrika Johansson, Sergio Matarraz et al. · 2014 · Leukemia
3. Combined landscape of single-nucleotide variants and copy number alterations in clonal hematopoiesis
   Ryunosuke Saiki, Yukihide Momozawa, Yasuhito Nannya, Masahiro Marshall Nakagawa, Yotaro Ochi, Tetsuichi Yoshizato, Chikashi Terao, Yutaka Kuroda, Yuichi Shiraishi, Kenichi Chiba et al. · 2021 · Nature Medicine
4. Ezh2 loss in hematopoietic stem cells predisposes mice to develop heterogeneous malignancies in an Ezh1-dependent manner
   Makiko Mochizuki‐Kashio, Kazumasa Aoyama, Goro Sashida, Motohiko Oshima, Takahisa Tomioka, Tomoya Muto, Changshan Wang, Atsushi Iwama · 2015 · Blood
5. Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia
   Seki, Masafumi, Kimura, Shunsuke, Isobe, Tomoya, Yoshida, Kenichi, Ueno, Hiroo, Nakajima-Takagi, Yaeko, Wang, Changshan, Lin, Lin, Kon, Ayana, Suzuki, Hiromichi et al. · 2017 · Nature Genetics
6. Validation of WHO classification-based Prognostic Scoring System (WPSS) for myelodysplastic syndromes and comparison with the revised International Prognostic Scoring System (IPSS-R). A study of the International Working Group for Prognosis in Myelodysplasia (IWG-PM)
   Matteo Giovanni Della Porta, Heinz Tuechler, Luca Malcovati, Julie Schanz, Guillermo Francisco Sanz, Guillermo Garcia‐Manero, Francesc Gessé Solé, John M. Bennett, David Bowen, Pierre Fenaux et al. · 2015 · Leukemia
7. RAS-pathway mutation patterns define epigenetic subclasses in juvenile myelomonocytic leukemia
   Daniel B. Lipka, Tania Witte, Réka Tóth, Jing Yang, Manuel Wiesenfarth, Peter Noellke, Alexandra Fischer, David Brocks, Zuguang Gu, Jeongbin Park et al. · 2017 · Nature Communications
8. Challenges in the introduction of next-generation sequencing (NGS) for diagnostics of myeloid malignancies into clinical routine use
   Ulrike Bacher, Evgenii Shumilov, Johanna Flach, Naomi Azur Porret, Raphael Joncourt, Gertrud Wiedemann, Martin Fiedler, Urban Novak, Ursula Amstutz, Thomas Pabst · 2018 · Blood Cancer Journal
9. Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes
   Montalban-Bravo, Guillermo, Kanagal-Shamanna, Rashmi, Benton, Christopher B., Class, Caleb A., Chien, Kelly S., Sasaki, Koji, Naqvi, Kiran, Alvarado, Yesid, Kadia, Tapan M., Ravandi, Farhad et al. · 2020 · Blood Advances
10. Splicing factor gene mutations in hematologic malignancies
    Borja Sáez, Matthew J. Walter, Timothy Aaron Graubert · 2016 · Blood
11. Emerging roles of spliceosome in cancer and immunity
    Hui Yang, Bruce Beutler, Duanwu Zhang · 2021 · Protein & Cell
12. Clonal hematopoiesis: Mutation-specific adaptation to environmental change
    Florez, Marcus A., Tran, Brandon T., Wathan, Trisha K., DeGregori, James, Pietras, Eric M., King, Katherine Y. · 2022 · Cell Stem Cell
13. DOT1L as a therapeutic target for the treatment of DNMT3A-mutant acute myeloid leukemia
    Rachel E. Rau, Benjamin A.T. Rodriguez, Min Luo, Mira Jeong, Allison Rosen, Jason H. Rogers, Carly T. Campbell, Scott R. Daigle, Lishing Deng, Yongcheng Song et al. · 2016 · Blood
14. Mutational profiling of therapy-related myelodysplastic syndromes and acute myeloid leukemia by next generation sequencing, a comparison with de novo diseases
    Chi Young Ok, Keyur Pravinchandra Patel, Guillermo Garcia‐Manero, Mark J. Routbort, Bin Fu, Guilin Tang, Maitrayee Goswami, Rajesh R. Singh, Rashmi Kanagal‐Shamanna, Sherry A. Pierce et al. · 2014 · Leukemia Research
15. Mutational hierarchies in myelodysplastic syndromes dynamically adapt and evolve upon therapy response and failure
    Maximilian Mossner, Johann-Christoph Jann, Janina Wittig, Florian Nolte, Stéphanie Fey, Verena Nowak, Julia Obländer, Jovita Pressler, Iris Palme, Christina Xanthopoulos et al. · 2016 · Blood
16. Hemopoietic-specific Sf3b1-K700E knock-in mice display the splicing defect seen in human MDS but develop anemia without ring sideroblasts
    Annalisa Mupo, Michael Seiler, Vijitha Sathiaseelan, Alena Pance, Yi‐Tsung Yang, Anant A. Agrawal, Francesco Iorio, Ruben Bautista, Suruchi Pacharne, Konstantinos Tzelepis et al. · 2016 · Leukemia
17. Mutation Clearance after Transplantation for Myelodysplastic Syndrome
    Eric J. Duncavage, Meagan A. Jacoby, Gue Su Chang, Christopher A. Miller, Natasha Catherine Edwin, Jin Shao, Kevin Elliott, Joshua Robinson, Haley Abel, Robert S. Fulton et al. · 2018 · New England Journal of Medicine
18. Disease-Causing Mutations in SF3B1 Alter Splicing by Disrupting Interaction with SUGP1
    Jian Zhang, Abdullah Mahmood Ali, Yen K. Lieu, Zhaoqi Liu, Jianchao Gao, Raúl Rabadán, Azra Raza, Siddhartha Mukherjee, James L. Manley · 2019 · Molecular Cell
19. PRPF8 defects cause missplicing in myeloid malignancies
    Amina Kurtović-Kozarić, Bartlomiej P. Przychodzen, Jagjit Singh, Maria M. Konarska, Michael J. Clemente, Zaher K. Otrock, Megan O. Nakashima, Eric D. Hsi, Kenichi Yoshida, Yuichi Shiraishi et al. · 2014 · Leukemia
20. Mutant U2AF1-expressing cells are sensitive to pharmacological modulation of the spliceosome
    Cara Lunn Shirai, Brian S. White, Manorama Tripathi, ROBERTO C. TAPIA-CONYER, James N. Ley, Matthew Ndonwi, Sanghyun Peter Kim, Jin Shao, Alexa Carver, Borja Sáez et al. · 2017 · Nature Communications
21. Molecular pathogenesis of the myeloproliferative neoplasms
    Graeme Greenfield, Mary Frances McMullin, Ken Mills · 2021 · Journal of Hematology & Oncology
22. The molecular pathogenesis of the myelodysplastic syndromes
    Andrea Pellagatti, Jacqueline Boultwood · 2015 · European Journal Of Haematology
23. IDH1 and IDH2 mutations in myelodysplastic syndromes and role in disease progression
    Courtney Denton Dinardo, Elias Joseph Jabbour, Farhad Ravandi, Koichi Takahashi, Naval Guastad Daver, Mark J. Routbort, Keyur Pravinchandra Patel, Mark Brandt, Sherry A. Pierce, Hagop M. Kantarjian et al. · 2015 · Leukemia
24. Genomic determinants of chronic myelomonocytic leukemia
    Bhumika J. Patel, Bartlomiej P. Przychodzen, Swapna Thota, Tomas Radivoyevitch, Valeria Visconte, Teodora Kuzmanovic, Michael J. Clemente, Cassandra M. Hirsch, Aaron R. Morawski, Roy Souaid et al. · 2017 · Leukemia
25. TET2 as an epigenetic master regulator for normal and malignant hematopoiesis
    Hideaki Nakajima, Hiroyoshi Kunimoto · 2014 · Cancer Science
26. Myelodysplastic syndromes: moving towards personalized management
    Eva Hellström‐Lindberg, Magnus Tobiasson, Peter L. Greenberg · 2020 · Haematologica
27. Myelodysplastic syndromes: 2015 Update on diagnosis, risk‐stratification and management
    Guillermo Garcia‐Manero · 2015 · American Journal of Hematology
28. IDH1/2 Mutations Sensitize Acute Myeloid Leukemia to PARP Inhibition and This Is Reversed by IDH1/2-Mutant Inhibitors
    Remco Jurriaan Molenaar, Tomas Radivoyevitch, Yasunobu Nagata, Mohammed Khurshed, Bartolomiej Przychodzen, Hideki Makishima, Mingjiang Xu, Fonnet E. Bleeker, Johanna W. Wilmink, Hetty E. Carraway et al. · 2018 · Clinical Cancer Research
29. Genetic abnormalities and pathophysiology of MDS
    Naoko Hosono · 2019 · International Journal of Clinical Oncology
30. Spliceosomal gene mutations in myelodysplasia: molecular links to clonal abnormalities of hematopoiesis
    Daichi Inoue, Robert K. Bradley, Omar Ibrahim Abdel-Wahab · 2016 · Genes & Development
31. Central and Peripheral Metabolic Defects Contribute to the Pathogenesis of Alzheimer's Disease: Targeting Mitochondria for Diagnosis and Prevention
    Peng, Yunhua, Gao, Peipei, Shi, Le, Chen, Lei, Liu, Jiankang, Long, Jiangang · 2020 · Antioxidants & Redox Signaling
32. Minor intron retention drives clonal hematopoietic disorders and diverse cancer predisposition
    Daichi Inoue, Jacob Tyler Polaski, Justin Taylor, Pau Castel, Sisi Chen, Susumu S. Kobayashi, Simon J. Hogg, Yasutaka Hayashi, Jose Mario Bello Pineda, Ettaib El Marabti et al. · 2021 · Nature Genetics
33. Mutations of myelodysplastic syndromes (MDS): An update
    Bani Bandana Ganguly, Nitin N. Kadam · 2016 · Mutation Research/Reviews in Mutation Research
34. Dynamic changes in the clonal structure of MDS and AML in response to epigenetic therapy
    Geoffrey L. Uy, Eric James Duncavage, Gue Su Chang, Meagan A. Jacoby, C A Miller, Jin Shao, Simon Charles Heath, Kevin Elliott, Teresa Reineck, R S Fulton et al. · 2016 · Leukemia
35. Clonal Hematopoiesis of Indeterminate Potential
    Michael Heuser, Felicitas R. Thol, Arnold Ganser · 2016 · Deutsches Ärzteblatt international
36. Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)—a study of 1084 patients
    Giacomo Coltro, Abhishek Avinash Mangaonkar, Terra L. Lasho, Christy M. Finke, Prateek A. Pophali, Ryan Michael Carr, Naseema Gangat, Moritz Binder, Animesh Dev Pardanani, Martín E. Fernández-Zapico et al. · 2019 · Leukemia
37. Relationship between clone metrics and clinical outcome in clonal cytopenia
    Anna Gallì, Gabriele Todisco, Eulalia Catamo, Cinzia Felicita Sala, Chiara Elena, Sara Pozzi, Elisa B. Bono, Virginia Valeria Ferretti, Ettore Rizzo, Elisabetta Molteni et al. · 2021 · Blood
38. Eprenetapopt triggers ferroptosis, inhibits NFS1 cysteine desulfurase, and synergizes with serine and glycine dietary restriction
    Fujihara, Kenji M., Zhang, Bonnie Z., Jackson, Thomas D., Ogunkola, Moses O., Nijagal, Brunda, Milne, Julia V., Sallman, David A., Ang, Ching-Seng, Nikolic, Iva, Kearney, Conor J. et al. · 2022 · Science Advances
39. Splicing factor mutations in hematologic malignancies
    Sisi Chen, Salima Benbarche, Omar Ibrahim Abdel-Wahab · 2021 · Blood
40. Mutations in G protein β subunits promote transformation and kinase inhibitor resistance
    Akinori Yoda, Guillaume Adelmant, Jérôme Tamburini, Bjoern Chapuy, Nobuaki Shindoh, Yuka Yoda, Oliver Weigert, Nadja Kopp, Shuo-Chieh Wu, Sunhee S. Kim et al. · 2014 · Nature Medicine
41. The splicing factor U2AF1 contributes to cancer progression through a noncanonical role in translation regulation
    Murali Palangat, Dimitrios G. Anastasakis, Dennis Liang Fei, Katherine E. Lindblad, Robert K. Bradley, Christopher Simon Hourigan, Markus Hafner, Daniel R. Larson · 2019 · Genes & Development
42. Clinical and genetic predictors of prognosis in myelodysplastic syndromes
    Rafael L. Bejar · 2014 · Haematologica
43. Signal Transduction in Ribosome Biogenesis: A Recipe to Avoid Disaster
    Manuela Piazzi, Alberto Bavelloni, Angela Gallo, Irene Faenza, William L. Blalock · 2019 · International Journal of Molecular Sciences
44. Clinical implications of TP53 mutations in myelodysplastic syndromes treated with hypomethylating agents
    Koichi Takahashi, Keyur Pravinchandra Patel, Carlos Bueso-Ramos, Jianhua Zhang, Curtis E. Gumbs, Elias Joseph Jabbour, Tapan Mahendra Kadia, Michael Andreff, Marina Y Konopleva, Courtney Denton Dinardo et al. · 2016 · Oncotarget
45. Anti‐tumor efficacy of a novel CLK inhibitor via targeting RNA splicing and MYC‐dependent vulnerability
    Kenichi Iwai, Masahiro Yaguchi, Kazuho Nishimura, Yukiko Yamamoto, Toshiya Tamura, Daisuke Nakata, Ryo Dairiki, Yoichi Kawakita, Ryo Mizojiri, Yoshiteru Ito et al. · 2018 · EMBO Molecular Medicine
46. Current challenges and unmet medical needs in myelodysplastic syndromes
    Uwe Platzbecker, Anne Sophie Kubasch, Collin Homer-Bouthiette, Thomas Prébet · 2021 · Leukemia
47. Multiplex CRISPR/Cas9-Based Genome Editing in Human Hematopoietic Stem Cells Models Clonal Hematopoiesis and Myeloid Neoplasia
    Zuzana Tóthová, John Michael Krill-Burger, Katerina D. Popova, Catherine C. Landers, Quinlan L. Sievers, David Yudovich, Roger Belizaire, Jon Christopher Aster, Elizabeth A. Morgan, Aviad Tsherniak et al. · 2017 · Cell stem cell
48. The biological function and clinical significance of SF3B1 mutations in cancer
    Zhixia Zhou, Qi Gong, Yin Wang, Mengkun Li, Lu Wang, Hongfei Ding, Peifeng Li · 2020 · Biomarker Research
49. The Spectrum and Clinical Impact of Epigenetic Modifier Mutations in Myeloma
    Charlotte Pawlyn, Martin Kaiser, Christoph Johann Heuck, Lorenzo Melchor, Christopher P. Wardell, Alex Murison, Shweta S. Chavan, David C. Johnson, Dil B Begum, Nasrin M. Dahir et al. · 2016 · Clinical Cancer Research
50. CHIP, CCUS, and Other Acronyms: Definition, Implications, and Impact on Practice
    Amy Elizabeth Dezern, Luca Malcovati, Benjamin L. Ebert · 2019 · American Society of Clinical Oncology Educational Book
51. Interplay between chromosomal alterations and gene mutations shapes the evolutionary trajectory of clonal hematopoiesis
    Teng Gao, Ryan N. Ptashkin, Kelly L. Bolton, Maria Sirenko, Christopher Fong, Barbara G. Spitzer, Kamal N. Menghrajani, Juan Arango Ossa, Yangyu Zhou, Elsa Bernard et al. · 2021 · Nature Communications
52. Synthetic Data Generation by Artificial Intelligence to Accelerate Research and Precision Medicine in Hematology
    Saverio D’Amico, Daniele Dall’Olio, Claudia Sala, Lorenzo Dall’Olio, Elisabetta Sauta, Matteo Zampini, Gianluca Asti, Luca Lanino, Giulia Maggioni, Alessia Campagna et al. · 2023 · JCO Clinical Cancer Informatics
53. Azacitidine with or without eltrombopag for first-line treatment of intermediate- or high-risk MDS with thrombocytopenia
    Michael John Dickinson, Honar Cherif, Pierre Fenaux, Moshe Mittelman, Amit K. Verma, Maria Socorro O Portella, Paul Burgess, Pedro Marques Ramos, Jeea Choi, Uwe Platzbecker · 2018 · Blood
54. 5-Hydroxymethylcytosine: An epigenetic mark frequently deregulated in cancer
    Leonie I. Kroeze, Bert A. van der Reijden, Joop H. Jansen · 2015 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
55. Prognostic impact of circulating tumor DNA status post–allogeneic hematopoietic stem cell transplantation in AML and MDS
    Sousuke Nakamura, Kazuaki Yokoyama, Eigo Shimizu, Nozomi Yusa, Kanya Kondoh, Miho Ogawa, Tomomi Takei, Asako Kobayashi, Mika Ito, Masamichi Isobe et al. · 2019 · Blood
56. SF3B1 mutations induce R-loop accumulation and DNA damage in MDS and leukemia cells with therapeutic implications
    Shalini Singh, Doaa Ahmed, Hamid Dolatshad, Dharamveer Tatwavedi, Ulrike Schulze, Andrea Sanchi, Sarah Ryley, Ashish Dhir, Lee Carpenter, Suzanne M. Watt et al. · 2020 · Leukemia
57. Clinical and biological implications of ancestral and non-ancestral IDH1 and IDH2 mutations in myeloid neoplasms
    Remco Jurriaan Molenaar, Swapna Thota, Yasunobu Nagata, Bhumika J. Patel, Michael J. Clemente, Bartlomiej P. Przychodzen, Cassandra M. Hirsch, Aaron D. Viny, N Hosano, Fonnet E. Bleeker et al. · 2015 · Leukemia
58. SETBP1 mutations drive leukemic transformation in ASXL1-mutated MDS
    Daichi Inoue, Jiro Kitaura, Hirotaka Matsui, H-A Hou, W-C Chou, Akiko Nagamachi, Kimihito Cojin Kawabata, Katsuhiro Togami, Reina Nagase, S Horikawa et al. · 2014 · Leukemia
59. Emerging concepts of epigenetic dysregulation in hematological malignancies
    Panagiotis Ntziachristos, Omar Ibrahim Abdel-Wahab, Iannis Aifantis · 2016 · Nature Immunology
60. Clinical, histopathological and molecular characterization of hypoplastic myelodysplastic syndrome
    Elisa B. Bono, Donal P. McLornan, Erica Travaglino, Shreyans Gandhi, Anna Gallì, Alesia Abigael Khan, Austin Gladston Kulasekararaj, Emanuela Boveri, Kavita K Raj, Chiara Elena et al. · 2019 · Leukemia
61. Incorporation of mutations in five genes in the revised International Prognostic Scoring System can improve risk stratification in the patients with myelodysplastic syndrome
    Hsin‐An Hou, Cheng‐Hong Tsai, Chien‐Chin Lin, Wen‐Chien Chou, Yuan‐Yeh Kuo, Chieh‐Yu Liu, Mei‐Hsuan Tseng, Yen‐Ling Peng, Ming-Chih Liu, Chia‐Wen Liu et al. · 2018 · Blood Cancer Journal
62. Gene mutational analysis by NGS and its clinical significance in patients with myelodysplastic syndrome and acute myeloid leukemia
    Jifeng Yu, Yingmei Li, Tao Li, Yafei Li, Haizhou Xing, Hui Sun, Ling Sun, Dingming Wan, Yanfang Liu, Xinsheng Xie et al. · 2020 · Experimental Hematology and Oncology
63. Defining AML and MDS second cancer risk dynamics after diagnoses of first cancers treated or not with radiation
    Tomas Radivoyevitch, Rainer K. Sachs, Robert Peter Gale, Remco Jurriaan Molenaar, David J. Brenner, Brian Thomas Hill, M. E. Kalaycio, Hetty E. Carraway, Sudipto Mukherjee, Mikkael Aaron Sekeres et al. · 2015 · Leukemia
64. The shadowlands of MDS: idiopathic cytopenias of undetermined significance (ICUS) and clonal hematopoiesis of indeterminate potential (CHIP)
    Luca Malcovati, Mario Cazzola · 2015 · Hematology
65. Cohesin mutations alter DNA damage repair and chromatin structure and create therapeutic vulnerabilities in MDS/AML
    Zuzana Tóthová, Anne-Laure Valton, Rebecca A. Gorelov, Mounica Vallurupalli, John Michael Krill-Burger, Amie L. Holmes, Catherine C. Landers, J. Erika Haydu, Edyta Małolepsza, Christina R. Hartigan et al. · 2020 · JCI Insight
66. Sex-Biased ZRSR2 Mutations in Myeloid Malignancies Impair Plasmacytoid Dendritic Cell Activation and Apoptosis
    Katsuhiro Togami, Sun Sook Chung, Vikas Madan, Christopher A.G. Booth, Christopher M. Kenyon, Lucía Cabal‐Hierro, Justin Taylor, Sunhee S. Kim, Gabriel Kenneth Griffin, Mahmoud Ghandi et al. · 2021 · Cancer Discovery
67. Guiding the global evolution of cytogenetic testing for hematologic malignancies
    Yassmine M. N. Akkari, Linda Banovic Baughn, Adrian M. Dubuc, Adam C. Smith, Mar Mallo, Paola Dal Cin, María Díez‐Campelo, Marta Susana Gallego, Isabel Granada, Detlef Thomas Haase et al. · 2022 · Blood
68. Myelodysplastic syndromes
    Huan Li, Fang Hu, Robert Peter Gale, Mikkael Aaron Sekeres, Yang Liang · 2022 · Nature Reviews Disease Primers
69. Molecular taxonomy of myelodysplastic syndromes and its clinical implications
    Elsa Bernard, Robert Paul Hasserjian, Peter L. Greenberg, Juan Arango Ossa, Maria Creignou, Heinz Tuechler, Jesús Gutiérrez‐Abril, Dylan Domenico, Juan Santiago Medina-Martinez, Max Fine Levine et al. · 2024 · Blood
70. Mutational landscape in children with myelodysplastic syndromes is distinct from adults: specific somatic drivers and novel germline variants
    V Pastor, Shinsuke Hirabayashi, Axel Karow, Julius Wehrle, Emilia J. Kozyra, Ronny Nienhold, Gunda Ruzaike, Dirk Lebrecht, Ayami Yoshimi, Marena Rebekka Niewisch et al. · 2016 · Leukemia
71. Mutations in spliceosome genes and therapeutic opportunities in myeloid malignancies
    Justin Taylor, Stanley Chun-Wei Lee · 2019 · Genes Chromosomes and Cancer
72. Telomere attrition and candidate gene mutations preceding monosomy 7 in aplastic anemia
    Bogdan Dumitriu, Xingmin Feng, Danielle Michelle Townsley, Yasutaka Ueda, Tetsuichi Yoshizato, Rodrigo T. Calado, Yanqin Yang, Yoshiyuki Wakabayashi, Sachiko Kajigaya, Seishi Ogawa et al. · 2014 · Blood
73. Genomic landscape of neutrophilic leukemias of ambiguous diagnosis
    Haijiao Zhang, Beth Wilmot, Daniel Bottomly, Kim-Hien T. Dao, Emily A. Stevens, Christopher A. Eide, Vishesh Khanna, Angela Rofelty, Samantha L. Savage, Anna Reister Schultz et al. · 2019 · Blood
74. Combined Cohesin–RUNX1 Deficiency Synergistically Perturbs Chromatin Looping and Causes Myelodysplastic Syndromes
    Yotaro Ochi, Ayana Kon, Toyonori Sakata, Masahiro Marshall Nakagawa, Naotaka Nakazawa, Masanori Kakuta, Keisuke Kataoka, Haruhiko Koseki, Manabu Nakayama, Daisuke Morishita et al. · 2020 · Cancer Discovery
75. Epigenetics in the hematologic malignancies
    Chun Yew Fong, Jessica Morison, Mark A. Dawson · 2014 · Haematologica
76. Physiological Srsf2 P95H expression causes impaired hematopoietic stem cell functions and aberrant RNA splicing in mice
    Ayana Kon, Satoshi Yamazaki, Yasuhito Nannya, Keisuke Kataoka, Yasunori Ota, Masahiro Marshall Nakagawa, Kenichi Yoshida, Yusuke Shiozawa, Maiko Morita, Tetsuichi Yoshizato et al. · 2017 · Blood
77. Integrating the “Immunome” in the Stratification of Myelodysplastic Syndromes and Future Clinical Trial Design
    Susann Winter, Saeed Shoaie, Shahram Y. Kordasti, Uwe Platzbecker · 2020 · Journal of Clinical Oncology
78. Molecular impact of mutations in RNA splicing factors in cancer
    Qian Zhang, Yuxi Ai, Omar Ibrahim Abdel-Wahab · 2024 · Molecular Cell
79. Gene expression and risk of leukemic transformation in myelodysplasia
    Yusuke Shiozawa, Luca Malcovati, Anna Gallì, Andrea Pellagatti, Mohsen Karimi, Aiko Sato‐Otsubo, Yusuke Sato, Hiromichi Suzuki, Tetsuichi Yoshizato, Kenichi Yoshida et al. · 2017 · Blood
80. High-throughput sequencing for noninvasive disease detection in hematologic malignancies
    Florian Scherer, David Matthew Kurtz, Maximilian Diehn, Ash A. Alizadeh · 2017 · Blood
81. A DNA target-enrichment approach to detect mutations, copy number changes and immunoglobulin translocations in multiple myeloma
    Niccolò Bolli, Y Li, Vijitha Sathiaseelan, Keiran M. Raine, David Jones, Peter S. Ganly, Federica Cocito, Graham R. Bignell, M A Chapman, Adam Samuel Sperling et al. · 2016 · Blood Cancer Journal
82. SF3B1 mutant MDS-initiating cells may arise from the haematopoietic stem cell compartment
    Syed A. Mian, Kevin Rouault‐Pierre, Alexander Smith, Thomas Seidl, Irene Pizzitola, Aytug Kizilors, Austin Gladston Kulasekararaj, Dominique A. Bonnet, Ghulam Jeelani Mufti · 2015 · Nature Communications
83. Phase III, Randomized, Placebo-Controlled Trial of CC-486 (Oral Azacitidine) in Patients With Lower-Risk Myelodysplastic Syndromes
    Guillermo Garcia‐Manero, Valeria Santini, Antonio Medina Almeida, Uwe Platzbecker, Anna T Jonasova, Lewis R. Silverman, Jose Francisco Falantes, Gianluigi Reda, Francesco Buccisano, Pierre Fenaux et al. · 2021 · Journal of Clinical Oncology
84. Cohesin Mutations in Cancer
    Magali De Koninck, Ana Losada · 2016 · Cold Spring Harbor Perspectives in Medicine
85. SF3B1-initiating mutations in MDS-RSs target lymphomyeloid hematopoietic stem cells
    Teresa Mortera Blanco, Marios Dimitriou, Petter S. Woll, Mohsen Karimi, Edda María Elvarsdóttir, Simona Conte, Magnus Tobiasson, Monika Jansson, Iyadh Douagi, Matahi Moarii et al. · 2017 · Blood
86. Targeting splicing abnormalities in cancer
    Anant A. Agrawal, Lihua Yu, Peter G. Smith, Silvia Buonamici · 2017 · Current Opinion in Genetics & Development
87. Baseline and serial molecular profiling predicts outcomes with hypomethylating agents in myelodysplastic syndromes
    Hunter, Anthony M., Komrokji, Rami S., Yun, Seongseok, Al Ali, Najla, Chan, Onyee, Song, Jinming, Hussaini, Mohammad, Talati, Chetasi, Sweet, Kendra L., Lancet, Jeffrey E. et al. · 2021 · Blood Advances
88. Targeted next‐generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS‐R
    Ayalew Tefferi, Terra L. Lasho, Mrinal M. Patnaik, Lyla Saeed, Mythri Mudireddy, Dame W. Idossa, Christy M. Finke, Rhett P. Ketterling, Animesh Dev Pardanani, Naseema Gangat · 2017 · American Journal of Hematology
89. The genetic and molecular pathogenesis of myelodysplastic syndromes
    Rory Michael Shallis, Rami Ahmad, Amer Methqal Zeidan · 2018 · European Journal Of Haematology
90. RUNX1‐dependent mechanisms in biological control and dysregulation in cancer
    Deli Hong, Andrew J. Fritz, Jonathan A. R. Gordon, Coralee E. Tye, Joseph R. Boyd, Kirsten M. Tracy, Seth E. Frietze, Frances E. Carr, Jeffrey A. Nickerson, André J. van Wijnen et al. · 2018 · Journal of Cellular Physiology
91. Machine learning demonstrates that somatic mutations imprint invariant morphologic features in myelodysplastic syndromes
    Yasunobu Nagata, Ran Zhao, Hassan K. Awada, Cassandra M Kerr, Inom Mirzaev, Sunisa Kongkiatkamon, Aziz Nazha, Hideki Makishima, Tomas Radivoyevitch, Jacob G. Scott et al. · 2020 · Blood
92. TP53 mutations predict decitabine‐induced complete responses in patients with myelodysplastic syndromes
    Chunkang Chang, Youshan Zhao, Feng Xu, Juan Guo, Zheng Zhang, Qi He, Dong Wu, Lingyun Wu, Jiying Su, Lu‐Xi Song et al. · 2016 · British Journal of Haematology
93. Age-Associated TET2 Mutations: Common Drivers of Myeloid Dysfunction, Cancer and Cardiovascular Disease
    Christina K. Ferrone, Mack Blydt-Hansen, Michael J. Rauh · 2020 · International Journal of Molecular Sciences
94. Paroxysmal nocturnal hemoglobinuria and telomere length predicts response to immunosuppressive therapy in pediatric aplastic anemia
    Atsushi Narita, Hideki Muramatsu, Y. Sekiya, Yusuke Okuno, Hiroshi Sakaguchi, N. Nishio, N. Yoshida, Xinan Wang, Yinyan Xu, Nozomu Kawashima et al. · 2015 · Haematologica
95. Efficacy of azacitidine is independent of molecular and clinical characteristics - an analysis of 128 patients with myelodysplastic syndromes or acute myeloid leukemia and a review of the literature
    Andrea Kuendgen, Catharina Müller‐Thomas, Michael Lauseker, Torsten Haferlach, Petra Urbaniak, Thomas A. Schroeder, Carolin Brings, Michael Wulfert, Manja Meggendorfer, Barbara Hildebrandt et al. · 2018 · Oncotarget
96. The 2016 revision to the World Health Organization classification of myelodysplastic syndromes
    Ming Hong, Guangsheng He · 2017 · Journal of Translational Internal Medicine
97. TET2 deficiency leads to stem cell factor–dependent clonal expansion of dysfunctional erythroid progenitors
    Xiaoli Qu, Shijie Zhang, Shihui Wang, Yaomei Wang, Wei Li, Yumin Huang, Huizhi Zhao, Xiuyun Wu, Chao An, Xinhua Guo et al. · 2018 · Blood
98. N6-methyladenosine mRNA marking promotes selective translation of regulons required for human erythropoiesis
    Daniel A. Kuppers, Sonali Arora, Yiting Lim, Andrea R. Lim, Lucas M. Carter, Philip D. Corrin, Christopher L. Plaisier, Ryan Basom, Jeffrey J. Delrow, Shiyan Wang et al. · 2019 · Nature Communications
99. Current and emerging strategies for management of myelodysplastic syndromes
    Saygin, Caner, Carraway, Hetty E. · 2021 · Blood Reviews
100. DNA methylation and hydroxymethylation in hematologic differentiation and transformation
     Myunggon Ko, Jungeun An, Anjana Rao · 2015 · Current Opinion in Cell Biology